GZ389988

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Osteoarthritis

Phase 1

First-in-human Study With Ascending Single Intra-articular Doses of GZ389988 in Patients With Painful Osteoarthritis of the Knee

CompletedNCT02424942

Genzyme, a Sanofi CompanyOsteoarthritis

Start: 2015-04-30End: 2016-07-31Updated: 2016-08-17

Phase 2

Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee

CompletedNCT02845271

Genzyme, a Sanofi CompanyOsteoarthritis

Start: 2016-07-21End: 2017-09-13Updated: 2022-04-13

Related Papers

Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study

Osteoarthritis and Cartilage2019-07-2540 citations